Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

Journal of the National Cancer Institute

Volumn 86, Issue 3, 1994, Pages 222-227

  Sartor, Oliver ^a   Cooper, Michael ^a   Weinberger, Maribeth ^a   Headlee, Donna ^a   Thibault, Alain ^a   Tompkins, Anne ^a   Steinberg, Seth ^a   Figg, William D ^a   Linehan, W Marston ^b   Myers, Charles E ^a  

^a National Cancer Institute ^*

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANGIOPEPTIN; BROMOCRIPTINE; DIETHYLSTILBESTROL; FLUTAMIDE; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM EXPOSURE; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUTAMIDE; HUMAN; MALE; MIDDLE AGE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0028089068     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.3.222     Document Type: Article

References (42)

1. Huggins C, Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res 1.293-297, 1941
2. Huggins C, Stevens RE, Hodges CV: Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223, 1941
3. Tolis G, Ackman D, Stellos A, et al: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormonereleasing hormone agonists, Proc Natl Acad Sci USA 79:1658-1662, 1982
4. Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology (DeVita VT Jr, Heilman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1985, pp 193-217
5. Labrie F, Dupont A, Belanger A, et al: New approach in the treatment of prostate cancen complete instead of partial withdrawal of androgens. Prostate 4:579-594, 1983
6. Alivizatos G, Oosterhof GO: Update of hormonal treatment in cancer of the prostate, Anticancer Drugs 4:301-309, 1993
7. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma, N Engl J Med 321:419-424, 1989
8. Janknegt RA, Abbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77-83, 1993
9. Denis LJ, Camelro de Moura JL, Bono A, ct al: Goserelin acetate and flutamide versus bilateral orchiectomy; a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42:119-130, 1993
10. Eisenberger MA, Simon R, O'Dwyer PJ, et al; A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
11. Kozlowski JM: Chemotherapy. J Urol 147:938-941, 1992
12. Myers C, Cooper M, Stein C, et al: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
13. Eisenberger MA, Reyno LM, Jodrell DI. et al: Suramin, an active drug for prostate cancer interim observations in a phase I trial. J Natl Cancer Inst 85:611-621. 1993
14. Wilding G, Chen M, Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115. 1989
15. Schuutmans AL, Bolt J, Veldscholte J, et al: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level, and acid phosphatase secretion. J Steroid Biochem Mol Biol 37:849-853, 1990
16. Veldscholte J, Ris-Stalpers C, Kuiper GG. et al: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Common 173:534-540, 1990
17. Samojiik E, Lippman AJ, Kirschner MA, et al: Medical adrenalectomy for prostate cancer clinical and hormonal effects. Am J Clin Oncol 11:579-585, 1988
18. Stein CA, Seville W, Yarchoan R, et al: Suramin and function of the adrenal cortex. Ann Intern Med 104:286-287, 1986
19. Fossa SD, Deamaley DP, Law M, et al: Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3:361-366, 1992
20. Scher H, Curley T, Yeh S, et al: Therapeutic alternatives for hormone-refractory prostate cancer. Semin Urol 10:55-64, 1992
21. Appendix A. Grading of toxicity. In Manual of Oncologic Therapeutics (Wittes RE, ed). Philadelphia: Lippincott, 1989, pp 627-632
22. Kaplan E, Meier P: Non-parametric estimation from incomplete observations, J Am Stat Assoc 53:457-481, 1958
23. Dowsett M, Mehta A, Cantwell BM, et al: Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. Eur J Cancer 27:846-849, 1991
24. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
25. Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761. 1992
26. Gerber GS, Chodák GW: Prostate specific antigen for assessing response to kétoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol 144:1177-1779, 1990
27. Fossa SD, Hosbach G. Paus E: Flutamide in hormone-resistant prostate cancer. J Urol 144:1411-1414, 1990
28. Ferro MA, Gillatt D, Symes MO, et al: High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 34:134-138, 1989
29. Scher HI, Curley T, Geller N, et al: Trimetrexate in prostatic cancer preliim-nary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1838, 1990
30. Kelly WK, Seber HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607-609, 1993
31. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
32. Dupont A, Gomez JL, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993
33. Bezwoda WR: Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone. Br J Urol 66:196-201, 1990
34. Labrie F, Dupont A, Belanger L, et al: Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br J Urol 63:634-638, 1989
35. Chang AY, Bennett JM, Pandya KJ, et al: A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate cancer. Am J Clin Oncol 12:358-360, 1989
36. Harland SJ, Duchesne GM: Suramin and prostate cancer: the role of hydrocortisone. Eur J Cancer 28A:1295, 1992
37. Vegeto E, Allan GF, Schrader WT. et al: The mechanism of RU486 antagonism is dependent on the conformation of the carhoxy-terminal tail of the human progesterone receptor. Cell 69:703-713, 1992
38. Garcia T, Benhamou B, Gofflo D, et al: Switching agonistic, antagonistic, and mixed transcriptional responses to 11 p-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 6:2071-2078, 1992
39. Jiang SY, Langan-Fahey SM, Stella AL, et al: Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 6:2167-2174, 1992
40. Liotta L, Stetler-Stevenson WG: Principles of molecular cell biology of cancer cancer metastasis: In Cancer, Principles and Practice of Oncology, 3rd ed (DeVita VT Jr, Heilman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1989, pp 98-115
41. Holliday R: Chromosome error propagation and cancer. Trends Genet 5:42-45, 1989
42. Howell A, Dodwell DJ, Anderson H, et al: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617, 1992